Cationic PEGylated polycaprolactone nanoparticles carrying post-operation docetaxel for glioma treatment

Creative Commons License

VARAN C., BİLENSOY E.

BEILSTEIN JOURNAL OF NANOTECHNOLOGY, cilt.8, ss.1446-1456, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8
  • Basım Tarihi: 2017
  • Doi Numarası: 10.3762/bjnano.8.144
  • Dergi Adı: BEILSTEIN JOURNAL OF NANOTECHNOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1446-1456
  • Anahtar Kelimeler: bioadhesive film, cationic nanoparticle, core-shell nanoparticle, docetaxel, glioma, CORE-SHELL NANOPARTICLES, LOCAL-DRUG DELIVERY, BLOOD-BRAIN-BARRIER, MELT EXTRUDED FILMS, LOADED NANOPARTICLES, MITOMYCIN-C, BIODEGRADABLE NANOPARTICLES, CHITOSAN NANOPARTICLES, ANTITUMOR EFFICACY, CANCER-TREATMENT
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Brain tumors are the most common tumors among adolescents. Although some chemotherapeutics are known to be effective against brain tumors based on cell culture studies, the same effect is not observed in clinical trials. For this reason, the development of drug delivery systems is important to treat brain tumors and prevent tumor recurrence. The aim of this study was to develop core-shell polymeric nanoparticles with positive charge by employing a chitosan coating. Additionally, an implantable formulation for the chemotherapeutic nanoparticles was developed as a bioadhesive film to be applied at the tumor site following surgical operation for brain glioma treatment. To obtain positively charged, implantable nanoparticles, the effects of preparation technique, chitosan coating concentration and presence of surfactants were evaluated to obtain optimal nanoparticles with a diameter of less than 100 nm and a net positive surface charge to facilitate cellular internalization of drug-loaded nanoparticles. Hydroxypropyl cellulose films were prepared to incorporate these nanoparticle dispersions to complete the implantable drug delivery system.